- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04116931
OPTImal Management of Antithrombotic Agents: OPTIMA-5
August 21, 2020 updated by: Chunjian Li, The First Affiliated Hospital with Nanjing Medical University
A Randomized Controlled Trial on the Switch From Ticagrelor to Clopidogrel in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention--OPTImal Management of Antithrombotic Agents: OPTIMA-5
This is a prospective, randomized, open-label clinical trial which will enroll 80 acute coronary syndrome (ACS) patients after Percutaneous Transluminal Coronary Intervention (PCI) in China.
Patients on maintenance dosing (MD) of aspirin (100 mg/d) and ticagrelor (90 mg twice daily) will be divided into two groups switching from ongoing ticagrelor to clopidogrel 600 mg loading dose (LD)/ 75 mg MD according to their bleeding risk.
Then each group will randomly switch at different times(24 hours/ 12 hours after the last MD of ticagrelor).
Pharmacodynamic assessments are performed at baseline, and at 4h, 8h, 24h, 48h, 72h hours with platelet aggregation rate by Light Transmittance Aggregometry method (LTA).
All patients are followed-up for 30 days.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The primary endpoint of the study was platelet inhibition measured by Light Transmittance Aggregometry method(LTA).
Secondary clinical endpoints included a 30-day major adverse cardiovascular endpoint (MACE) defined as a composite of cardiovascular death, recurrent myocardial infarction, target vessel revascularisation or stroke and individual components of the MACE.
Safety endpoints of 30-day TIMI major and minor bleed were also evaluated.
Study Type
Interventional
Enrollment (Anticipated)
80
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Qian Gu
- Phone Number: +86-18351972592
- Email: Solsticeg@163.com
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Recruiting
- First Affiliated Hospital of Nanjing Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- ≥ 18 years.
- ACS patients.
- Patients who are treated with ticagrelor and do not tolerate it.
- Volunteer to participate and sign informed consent.
- Approved by national regulatory authorities ethics committees.
Exclusion Criteria:
- Patients who are contraindicated, intolerant or resistant to clopidogrel.
- History of hematological disease or bleeding tendency; platelet count < 100 × 10^9 cells/L, or > 600 × 10^9 cells/L, hemoglobin < 100 g/L.
- Abnormal liver or kidney function (ALT > 3 ULN; estimated CrCl < 30 ml/min calculated by Cockcroft-Gault equation); diagnosed severe pulmonary disease.
- Patients in need of drugs which affect the efficacy of clopidogrel such as miconazole, ketoconazole, andfluconazole.
- Malignancies or other comorbid conditions with life expectancy less than 1 year.
- Pregnant or lactating woman.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: clopidogrel-600 mg-12h
clopidogrel 600 mg loading dose (LD) 12 hours after the last maintenance dose(MD) of ticagrelor followed by 75 mg MD daily
|
Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose(MD)12/24 hours after the last MD of ticagrelor
Other Names:
|
EXPERIMENTAL: clopidogrel-600 mg-24h
clopidogrel 600 mg loading dose (LD) 24 hours after the last maintenance dose(MD) of ticagrelor followed by 75 mg MD daily
|
Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose(MD)12/24 hours after the last MD of ticagrelor
Other Names:
|
EXPERIMENTAL: clopidogrel-75 mg-12h
clopidogrel 75 mg maintenance dose(MD) 12 hours after the last MD of ticagrelor
|
Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose(MD)12/24 hours after the last MD of ticagrelor
Other Names:
|
EXPERIMENTAL: clopidogrel-75 mg-24h
clopidogrel 75 mg maintenance dose(MD) 24 hours after the last MD of ticagrelor
|
Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose(MD)12/24 hours after the last MD of ticagrelor
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of platelet aggregation between different time points
Time Frame: baseline,4 hours,8 hours,24 hours,48 hours,72 hours
|
Regional differences between blood samples from each subjects of different groups by LTA.The results of LTA are reported in platelet aggregation rate(%).Platelet aggregation was induced by0.5mg/ml arachidonic acid (AA).
|
baseline,4 hours,8 hours,24 hours,48 hours,72 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of clinical endpoint event
Time Frame: 30 days
|
Secondary clinical endpoints included a 30-day major adverse cardiovascular endpoint (MACE) defined as a composite of cardiovascular death, recurrent myocardial infarction, target vessel revascularisation or stroke and individual components of the MACE.
Safety endpoints of 30-day TIMI major and minor bleed were also evaluated.
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Chunjian Li, Dr, PhD, Principal Investigator
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 22, 2020
Primary Completion (ANTICIPATED)
May 30, 2021
Study Completion (ANTICIPATED)
June 30, 2021
Study Registration Dates
First Submitted
September 26, 2019
First Submitted That Met QC Criteria
October 3, 2019
First Posted (ACTUAL)
October 7, 2019
Study Record Updates
Last Update Posted (ACTUAL)
August 25, 2020
Last Update Submitted That Met QC Criteria
August 21, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Disease
- Syndrome
- Acute Coronary Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Ticagrelor
- Clopidogrel
Other Study ID Numbers
- 011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndrome (ACS)
-
Canadian Institutes of Health Research (CIHR)Completed
-
Fundación Investigación Sanitaria en LeónAstraZenecaCompleted
-
Uppsala UniversityAbbott Medical Devices; The Medicines Company; InfraredxCompletedAcute Coronary Syndrome (ACS)Sweden
-
The Medicines CompanyCompletedAcute Coronary Syndrome (ACS)United States
-
Hainan People's HospitalRecruiting
-
AstraZenecaCompletedAcute Coronary Syndrome (ACS)China
-
Yonsei UniversityCompletedAcute Coronary Syndrome (ACS)Korea, Republic of
-
Yun Dai ChenUnknownACS - Acute Coronary SyndromeChina
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI); American Society of Health-System...CompletedAcute Coronary Syndrome (ACS)United States
Clinical Trials on Switch ticagrelor to clopidogrel
-
Collegium Medicum w BydgoszczyNot yet recruitingUnstable Angina | Non ST Segment Elevation Acute Coronary Syndrome | Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)Poland
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
The Third Xiangya Hospital of Central South UniversityCompletedCoronary Heart DiseaseChina
-
Calmy AlexandraCompletedAntiretroviral Therapy | HIV-1-infection | Maintenance TherapySwitzerland
-
Deutsches Herzzentrum MuenchenMedtronic; Klinikum Bamberg; Krankenhaus PeißenbergCompletedPacemaker Implantation for Sinus Node DiseaseGermany
-
Chinese PLA General HospitalUnknownCLOPIDOGREL, POOR METABOLISM of (Disorder)China
-
University Hospital, ToulouseCompletedAtherosclerosisFrance
-
Azienda Ospedaliera San Gerardo di MonzaGilead SciencesCompletedQuality of Life | HIV-1 Infection | Impaired Cognition | Poor Quality Sleep | Depression/AnxietyItaly
-
National Institute on Media and the FamilyUniversity of Minnesota; Michigan State University; Iowa State University; Cargill and other collaboratorsCompletedObesity | OverweightUnited States